Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.52 |
| ▸ | CDK4 | P11802 | 3/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 5/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7249032 | 0.81 | GRM4 (0.57) | CDK2GRM4DYRK1ANPC1MAPT | |
| SCHEMBL4677393 | 0.77 | GRM4 (0.52) | CDK2GRM4DYRK1ANPC1MAPT | |
| SCHEMBL27444164 | 0.76 | CDK2 (0.58) | CDK2CDK4CCNE1GSK3BKDR | |
| SCHEMBL4674162 | 0.75 | GRM4 (0.50) | CDK2CCNE1GRM4DYRK1AMAPK10 | |
| SCHEMBL12019062 | 0.72 | CDK2 (0.45) | CDK2GRM4DYRK1ALMNAHTT | |
| SCHEMBL13053954 | 0.71 | MAPK10 (0.70) | GSK3BMAPK10PRKCDABL1EGFR | |
| SCHEMBL6070014 | 0.71 | MAPK10 (0.52) | CDK2CDK4CCNE1GSK3BKDR | |
| SCHEMBL6596500 | 0.70 | CDK2 (0.64) | CDK2CDK4CCNE1GSK3BKDR | |
| SCHEMBL1593016 | 0.70 | PRKCD (0.79) | CDK2CDK4GSK3BPLK1CDK1 | |
| SCHEMBL27444265 | 0.70 | IKBKB (0.59) | CDK2CDK4GSK3BKDRPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1343781-B1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1343781-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020111353-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2002-08-15 | — | — | US | disclosed |
| WO-2002046184-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111353-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | MAPK1, MAPK3, MAPKAPK3 | CDK2 99/4885CDK4 644/4885CCNE1 810/4885 |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | CDK2 1753/4885CDK4 2927/4885CCNE1 4604/4885 |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | CDK2 1753/4885CDK4 2927/4885CCNE1 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.